| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S11886-010-0140-7 |
| P698 | PubMed publication ID | 20827517 |
| P50 | author | Suzanne Oparil | Q30029225 |
| Fadi G. Hage | Q37841344 | ||
| P2093 | author name string | Sulaf J Mansur | |
| P2860 | cites work | Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin | Q24298747 |
| Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril | Q28215905 | ||
| The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators | Q28372091 | ||
| Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients | Q29619542 | ||
| Telmisartan, ramipril, or both in patients at high risk for vascular events | Q33156143 | ||
| Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. | Q33414957 | ||
| 2010 Canadian Hypertension Education Program (CHEP) recommendations: the scientific summary - an update of the 2010 theme and the science behind new CHEP recommendations | Q33916665 | ||
| A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure | Q34106793 | ||
| Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction | Q34187441 | ||
| Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial | Q34246891 | ||
| Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction | Q34427866 | ||
| Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research | Q34788452 | ||
| Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension | Q36088984 | ||
| Inhibiting the renin-angiotensin system to prevent cardiovascular diseases: do we need a more comprehensive strategy? | Q36568400 | ||
| Dual blockade of the renin-angiotensin system in the progression of renal disease: the need for more clinical trials | Q36665920 | ||
| The incidence and implications of aldosterone breakthrough | Q36918649 | ||
| Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). | Q37087865 | ||
| Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria | Q37364926 | ||
| Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study | Q37368689 | ||
| Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination | Q37574913 | ||
| Beta-blockers for hypertension: are they going out of style? | Q37591017 | ||
| Reinventing the ACE inhibitors: some old and new implications of ACE inhibition | Q37632261 | ||
| Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both | Q39669015 | ||
| Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies | Q40982204 | ||
| Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial | Q42542786 | ||
| Efficacy of spironolactone therapy in patients with true resistant hypertension. | Q43254492 | ||
| Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure | Q43266277 | ||
| Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice | Q44053753 | ||
| Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients | Q44087052 | ||
| Efficacy of low-dose spironolactone in subjects with resistant hypertension | Q44628337 | ||
| Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption | Q45173412 | ||
| Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study. | Q45242324 | ||
| Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy | Q46157336 | ||
| Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design | Q46162422 | ||
| Renin inhibitors: novel agents for renoprotection or a better angiotensin receptor blocker for blood pressure lowering? | Q46311502 | ||
| Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. | Q46426098 | ||
| Aliskiren combined with losartan in type 2 diabetes and nephropathy | Q46558669 | ||
| Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats | Q46587391 | ||
| Ventricular and vascular remodelling effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients | Q46750956 | ||
| Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension | Q46801334 | ||
| Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase | Q47296079 | ||
| Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators | Q48118604 | ||
| Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document | Q56970676 | ||
| Combination Therapy Versus Monotherapy in Reducing Blood Pressure: Meta-analysis on 11,000 Participants from 42 Trials | Q58133760 | ||
| Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: Results of the IMPROVE trial | Q61455820 | ||
| Reactive Hyperreninemia Is a Major Determinant of Plasma Angiotensin II During ACE Inhibition | Q67654263 | ||
| Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response? | Q67858660 | ||
| The antiproteinuric action of enalapril in stroke-prone spontaneously hypertensive rats is unrelated to alterations in urinary prostaglandins | Q68071366 | ||
| Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia | Q73624366 | ||
| Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan | Q79470523 | ||
| Effect of spironolactone on blood pressure in subjects with resistant hypertension | Q79798622 | ||
| K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease | Q80010742 | ||
| Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial | Q80688403 | ||
| Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease | Q81555894 | ||
| Aldosterone and cardiovascular disease | Q83170067 | ||
| 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Deve | Q83631957 | ||
| Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors | Q84465799 | ||
| Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis | Q94691477 | ||
| P433 | issue | 6 | |
| P921 | main subject | cardiovascular disease | Q389735 |
| P304 | page(s) | 450-463 | |
| P577 | publication date | 2010-11-01 | |
| P1433 | published in | Current cardiology reports | Q26842345 |
| P1476 | title | Have the renin-angiotensin-aldosterone system perturbations in cardiovascular disease been exhausted? | |
| P478 | volume | 12 |
| Q45412026 | A blunted heart rate response to regadenoson is an independent prognostic indicator in patients undergoing myocardial perfusion imaging |
| Q55279696 | Epigenetic Programming of Synthesis, Release, and/or Receptor Expression of Common Mediators Participating in the Risk/Resilience for Comorbid Stress-Related Disorders and Coronary Artery Disease. |
| Q47410319 | Leukocyte RhoA exchange factor Arhgef1 mediates vascular inflammation and atherosclerosis |
| Q87365138 | Renin-angiotensin system blockade and pleiotropic cardiovascular effects: the novel angiotensin receptor blocker azilsartan |
| Q21284671 | The Renin-Angiotensin-aldosterone system in vascular inflammation and remodeling |
Search more.